Another Generic from Dr. Reddy's - Analyst Blog

By
A A A

Dr. Reddy's Laboratories ( RDY ) recently launched its generic version of Pfizer's ( PFE ) pulmonary arterial hypertension (PAH) drug, Revatio (sildenafil) tablets. We note that Dr. Reddy's is not the only company to launch a generic version of Revatio. Earlier this month, Mylan ( MYL ) had launched its generic version of the drug.

Apart from Mylan and Dr. Reddy's, Watson Pharmaceuticals ( WPI ) also gained approval for its generic version of Revatio. Watson Pharma intends to launch its product shortly.

According to IMS Health, US sales of Revatio tablets in the 12 months ending September 30, 2012, were $338.7 million. While Revatio tablets lost exclusivity in September 2012, Revatio intravenous injection is slated to lose exclusivity in May 2013.


During the second quarter of fiscal 2013, Dr. Reddy's launched 4 new generic products and filed 4 abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA).

Dr. Reddy's generics division delivered a strong performance in North America (47%) in the second quarter of fiscal 2013. Generics revenues were driven by limited competition for the company's generic versions of Pfizer's Geodon (ziprasidone), Astellas Pharma's Prograf (tacrolimus), GlaxoSmithKline's ( GSK ) Arixtra (fondaparinux) and Bristol-Myers Squibb's ( BMY ) and Sanofi's ( SNY ) Plavix (clopidogrel). Revenues were also boosted by products from the Shreveport facility and the ramp-up in the antibiotics portfolio.

Our Recommendation

We currently have an Outperform recommendation on Dr. Reddy's, which carries a Zacks #1 Rank (short term 'Strong Buy' rating). We are pleased with Dr. Reddy's geographic reach and product depth along with the robust generic product pipeline. We expect the US generics business to continue performing well in the coming quarters. Other generic companies like Mylan and Watson Pharma currently carry a Zacks #2 Rank (short-term 'Buy' rating).



BRISTOL-MYERS (BMY): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

MYLAN INC (MYL): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

DOCTOR REDDYS (RDY): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

WATSON PHARMA (WPI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BMY , GSK , MYL , PFE , RDY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com